TCRX - Latest News
TScan Therapeutics, Inc. (TCRX), operates in Healthcare / Biotechnology, trades on NASDAQ.
Market capitalization stands near $56.4M. Beta to the broader market is 1.04.
The article list below shows the most recent TCRX headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.
Recent TCRX Headlines
TScan Therapeutics to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
globenewswire.com - Jun 24, 2026
WALTHAM, Mass. , June 24, 2026 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc.
TScan Therapeutics Announces Positive Initial Data from Cohort C of Ongoing ALLOHA™ Phase 1 Study Evaluating TSC-101 in Patients with Heme Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation
globenewswire.com - Jun 22, 2026
11 of 14 patients dosed had complete donor chimerism within ~three weeks of receiving first infusion of TSC-101; an additional two had improving chime
Cellares and TScan Therapeutics Announce Agreement to Evaluate Automated Manufacturing of TSC-101 for Patients with Hematologic Malignancies
gurufocus.com - Jun 3, 2026
Cellares, the first Integrated Development and Manufacturing Organization (IDMO), and TScan Therapeutics, Inc.
Cellares and TScan Therapeutics Announce Agreement to Evaluate Automated Manufacturing of TSC-101 for Patients with Hematologic Malignancies
businesswire.com - Jun 3, 2026
SOUTH SAN FRANCISCO, Calif. & WALTHAM, Mass.
TScan Therapeutics, Inc. (TCRX) Reports Q1 Loss, Lags Revenue Estimates
zacks.com - May 6, 2026
TScan Therapeutics, Inc. (TCRX) came out with a quarterly loss of $0.
How News Affects TCRX Options Pricing
Headlines and scheduled events drive implied volatility in two distinct ways. Pre-event, IV typically inflates as uncertainty about the outcome rises; this is the implied-volatility expansion that creates the long-vol setup. Post-event, IV typically contracts sharply as uncertainty resolves; this is IV crush, which makes premium-selling structures profitable when they survive the underlying move. The size of the crush depends on how stretched pre-event IV is relative to the realized move. Track TCRX's implied vs realized volatility over the news cycle to size pre-event vs post-event positioning. For ticker-level dealer positioning context, the gamma exposure view shows whether dealers are positioned to amplify or dampen post-news moves.
Frequently asked TCRX news questions
- What is the latest TCRX news headline?
- The most recent TCRX headline (Jun 24, 2026) is "TScan Therapeutics to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference". The five most recent stories with summaries and publication times are listed above, sourced from major financial news vendors.
- How fresh is the TCRX news on this page?
- News rows refresh roughly every 30 minutes during the trading day. The five most recent headlines are listed in publication-time order. Press releases from the company itself typically appear within minutes of the wire release; third-party reporting may lag by 30-60 minutes depending on the source.
- What TCRX news moves options pricing?
- Three categories move single-name IV most aggressively: scheduled earnings releases (priced into pre-event IV, crushed post-event), unscheduled M&A or strategic announcements (rapid IV expansion, slower decay), and regulatory or legal events (drug-trial readouts, antitrust filings, FDA approvals). Routine news flow (analyst commentary, sector rotation) typically does not move IV meaningfully unless it triggers a cluster of rating changes.
- How can I track unusual TCRX options activity related to news?
- Unusual options activity often precedes news by hours to days; the canonical signals are volume substantially above the trailing average concentrated in a small number of strikes, atypical put/call skew, and aggressive execution (at-the-ask sweeps or block prints). Cross-reference the per-ticker gamma-exposure and volume-history pages with the news flow above to triangulate informed vs uninformed flow.